In 2017, the report found all low- and middle-income countries could access entecavir, which is used to treat hepatitis B, and all but two could access the infection treatment tenofovir.
Despite a decrease in the median price of generic tenofovir, from $208 per year of treatment in 2004 to $32 in 2016, treatment rates are still low, the CDC found.
“Taking advantage of reductions in price of antivirals active against [hepatitis B virus] infection could further increase access to treatment,” the agency wrote. “Regular analysis of the hepatitis B treatment care cascade can assist in monitoring progress toward [hepatitis B virus] elimination goals.”
More articles on clinical leadership and infection control:
Health officials praise Kentucky for hep A outbreak response
New hand hygiene data collection process uses Google
44 states affected by salmonella outbreak tied to live poultry
